Browse the search results

Anti-targets are proteins that cause problems when inhibited along with an intended target and our novel chemical strategy affords unprecedented selectivity in the context of FLT3 vs. KIT inhibition for treatment of a devastating blood cancer.

The combination of ceritinib with CGM097 demonstrates remarkable antitumor activity in TP53 wild-type neuroblastoma models with ALK aberrations and is able to overcome the resistance acquired during ceritinib treatment.

A novel genome-wide transcriptional activation screening in Drosophila cells revealed the activation of InR-Akt-mTOR pathway by cholesterol in plasma membrane to confer resistance to Rapamycin.

EZH2/cMET may serve as biomarkers to stratify chondrosarcoma patients for cMET inhibitor treatment.

Current understanding of Mertk biology, such as in retinal degeneration and tumor immunity, is redefined by gene knockout in C57BL/6 mice.

The functional relevance of stem cell niche perturbation in sarcomagenesis is defined and the mouse model presented provides a rationale for the use of combination therapy for the treatment of genetically heterogeneous sarcomas.

Classification of MET mutations allows a better understanding of sensitivity and resistance to targeted therapies used in cancer.

A four-switch long-range allosteric network controls FGF receptor kinase conformational dynamics as well as activity and is applicable to other receptor tyrosine kinases.

A new type of mRNAs-loaded CD133⁺ vesicles, named intercellsome, mediate cell-cell communications to compensate intracellular proliferative signal deficit, representing a previously unrecognized mechanism of cell proliferation under stress.